



IFW

Receipt

Atty Dkt. No. IRVN-007CON

USSN: 09/712,813

CERTIFICATE OF MAILING			
I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Office of Initial Patent Examination, Commissioner for Patents, P.O. Box 1450 Alexandria, VA 22313-1450.			
Typed or Printed Name	Martha Cisneros		
Signature		Date	7/22/04
REQUEST FOR CORRECTED FILING RECEIPT Address to: Mail Stop Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450		Attorney Docket	IRVN-007CON
		Applicant	GRANGER, GALE A.
		Serial Number	09/712,813
		Filing Date	November 13, 2000
		Group Art Unit	1646
		Examiner Name	MURPHY, JOSEPH F.
		Title:	" <i>TREATING ARTHRITIS WITH TNF RECEPTOR RELEASING ENZYME</i> "

Sir:

A filing receipt for the above-identified patent application has been issued by the Commissioner of Patents and has been found to contain errors as shown on the attached copy. Applicant respectfully requests that the Commissioner issue a corrected Official Filing Receipt.

If for any reason a fee is found to be necessary, the Commissioner is authorized to charge such fee to Deposit Account No. 50-0815.

Respectfully submitted,
BOZICEVIC, FIELD & FRANCIS LLP

Date: July 22, 2004

By:
Carol L. Francis
Registration No. 36,513

BOZICEVIC, FIELD & FRANCIS LLP
200 Middlefield Road, Suite 200
Menlo Park, CA 94025
Telephone: (650) 327-3400
Facsimile: (650) 327-3231



UNITED STATES PATENT AND TRADEMARK OFFICE

JUL 26 2004

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPL NO.	FILING OR 371 (c) DATE	ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO	DRAWINGS	TOT CLMS	IND CLMS
09/712,813	11/13/2000	1646	755	IRVN-007CON	5	10	2

CONFIRMATION NO. 4642

CORRECTED FILING RECEIPT



OC000000012901159

24353
BOZICEVIC, FIELD & FRANCIS LLP
200 MIDDLEFIELD RD
SUITE 200
MENLO PARK, CA 94025

Date Mailed: 06/10/2004

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Filing Receipt Corrections, facsimile number 703-746-9195. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Gale A. Granger, Laguna Beach, CA;
Tetsuya Gatanaga, Irvine, CA;

Domestic Priority data as claimed by applicant

This application is a CIP of 09/081,385 05/14/1998 PAT 6,593,456
which is a CIP of 08/964,747 11/05/1997 PAT 6,569,664
and claims benefit of 60/030,761 11/06/1996
and is a CON of PCT/US99/10793 05/14/1999

Foreign Applications

If Required, Foreign Filing License Granted: 03/30/2001

Projected Publication Date: None, application is not eligible for pre-grant publication

Non-Publication Request: No

Early Publication Request: No

** SMALL ENTITY **

Title

06/17/04
DOCKETED
RECEIVED

JUN 15 2004

RECEPTOR

TREATING ARTHRITIS WITH TNF RECEPTOR RELEASING ENZYME

Preliminary Class

530



**LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15**

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).